Other Clinical Trial - A Study of Famitinib in Combination With HS-10296

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT03333343` - Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC	Phase 1

See also

Status

Clinical Trial

Phase

Active, not recruiting

NCT03333343 - Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Phase 1

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03904823
Study type	Interventional
Source	Jiangsu HengRui Medicine Co., Ltd.
Contact	Quanren Wang, PhD
Phone	+86 18036618570
Email	wangquanren@hrglobe.cn
Status	Recruiting
Phase	Phase 2
Start date	April 25, 2019
Completion date	December 2022

A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms